|
1
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eltawil KM, Gustafsson BI, Kidd M and
Modlin IM: Neuroendocrine tumors of the gallbladder: An evaluation
and reassessment of management strategy. J Clin Gastroenterol.
44:687–695. 2010.PubMed/NCBI
|
|
3
|
Mizutani G, Nakanishi Y, Watanabe N, Honma
T, Obana Y, Seki T, Ohni S and Nemoto N: Expression of somatostatin
receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine
tumors using real-time RT-PCR method and immunohistochemistry. Acta
Histochem Cytochem. 45:167–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ayiomamitis GD, Notas G, Zaravinos A,
Drygiannakis I, Georgiadou M, Sfakianaki O, Mastrodimou N, Thermos
K and Kouroumalis E: Effects of octreotide and insulin on colon
cancer cellular proliferation and correlation with hTERT activity.
Oncoscience. 1:457–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Colucci R, Blandizzi C, Ghisu N, Florio T
and Del Tacca M: Somatostatin inhibits colon cancer cell growth
through cyclooxygenase-2 downregulation. Br J Phasrmacol.
155:198–209. 2008. View Article : Google Scholar
|
|
6
|
Albores-Saavedra J, Batich K, Hossain S,
Henson DE and Schwartz AM: Carcinoid tumors and small-cell
carcinomas of the gallbladder and extrahepatic bile ducts: A
comparative study based on 221 cases from the Surveillance,
Epidemiology, and End Results Program. Ann Diagn Pathol.
13:378–383. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yun SP, Shin N and Seo HI: Clinical
outcomes of small cell neuroendocrine carcinoma and adenocarcinoma
of the gallbladder. World J Gastroenterol. 21:269–275. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamilton SR and Aaltonen LA: World health
organization classification of tumours. Pathology and genetics of
tumours of the digestive system. Hamilton SR and Aaltonen LA: IARC
Press; Lyon: pp. 20002000
|
|
9
|
Adachi T, Haraguchi M, Irie J, Yoshimoto
T, Uehara R, Ito S, Tokai H, Noda K, Tada N and Hirabaru M:
Gallbladder small cell carcinoma: A case report and literature
review. Surg Case Rep. 2:712016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horiguchi S: A case of neuroendocrine
carcinoma of gallbladder. Tando. 30:290–297. 2016.
|
|
11
|
Chen C, Wang L, Liu X, Zhang G, Zhao Y and
Geng Z: Gallbladder neuroendocrine carcinoma: Report of 10 cases
and comparision of clinicopathologic features with gallbladder
adenocarcinoma. Int J Clin Exp Pathol. 8:8218–8226. 2015.PubMed/NCBI
|
|
12
|
El Fattach H, Guerrache Y, Eveno C, Pocard
M, Kaci R, Shaar-Chneker C, Dautry R, Boudiaf M, Dohan A and Soyer
P: Primary neuroendocrine tumors of the gallbladder:
Ultrasonographic and MDCT features with pathologic correlation.
Diagn Interv Imaging. 96:499–502. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murawaki Y, Miura M, Otani Y and Yoshida
M: A case of adenoendocrine cell carcinoma of the gallbladder
complicated by pancreaticobiliary maljunction, whereby differences
in tissue composition could be identified on diffusion-weighted
MRI. Tando. 27:200–204. 2013.
|
|
14
|
Ogawa T, Horaguchi J, Fujita N, Noda Y,
Kobayashi G, Ito K, Koshita S, Kanno Y, Masu K and Sugita R: High
b-value diffusion-weighted magnetic resonance imaging for
gallbladder lesions: Differentiation between benignity and
malignancy. J Gastroenterol. 47:1352–1360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Toole D, Kianmanesh R and Caplin M:
ENETS 2016 consensus guidelines for the management of patients with
digestive neuroendocrine tumors: An update. Neuroendocrinology.
103:117–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Essen M, Sundin A, Krenning EP and
Kwekkeboom DJ: Neuroendocrine tumours: The role of imaging for
diagnosis and therapy. Nat Rev Endocrinol. 10:102–114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Binderup T, Knigge U, Loft A, Mortensen J,
Pfeifer A, Federspiel B, Hansen CP, Højgaard L and Kjaer A:
Functional imaging of neuroendocrine tumors: A head-to-head
comparison of somatostatin receptor scintigraphy, 123I-MIBG
Scintigraphy, and 18F-FDG PET. J Nucl Med. 51:704–712. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kubota K, Okasaki M, Minamimoto R, Miyata
Y, Morooka M, Nakajima K and Sato T: Lesion-based analysis of
(18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine
tumors. Ann Nucl Med. 28:1004–1010. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Volante M, Brizzi MP, Faggiano A, La Rosa
S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C,
et al: Somatostatin receptor type 2A immunohistochemistry in
neuroendocrine tumors: A proposal of scoring system correlated with
somatostatin receptor scintigraphy. Mod Pathol. 20:1172–1182. 2007.
View Article : Google Scholar : PubMed/NCBI
|
